Anamirta Cocculus Seed Chenopodium Ambrosioides Co

證據等級: L5

預測適應症: 0 個

Homeopathic Compound (Nux Vomica / Pulsatilla / Cocculus Complex): Insufficient Evidence for Repurposing Analysis

One-Sentence Summary

This is a multi-ingredient homeopathic compound containing eight botanical and mineral substances — including Strychnos nux-vomica seed, Pulsatilla vulgaris, Conium maculatum, and Anamirta cocculus — with no US market authorization and no documented original indication. TxGNN generated no repurposing predictions for this compound, as it lacks a DrugBank ID and cannot be anchored to the knowledge graph. Before any repurposing analysis can proceed, foundational data collection is required.

Quick Overview

Item	Content
Original Indication	No regulatory data on record
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — prerequisite data absent
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

TxGNN returned zero repurposing candidates for this compound. Three structural barriers explain the failure:

1. No DrugBank ID. The TxGNN knowledge graph uses DrugBank identifiers as the primary anchor for drug nodes. Without this anchor, no drug–target–disease links can be retrieved and no prediction score can be computed.

2. Multi-ingredient homeopathic formulation. The compound contains eight distinct constituents, each requiring individual mapping before any multi-target modelling can be attempted:

Ingredient	Known Conventional Role
Strychnos nux-vomica seed	Contains strychnine/brucine (neurotoxic alkaloids)
Pulsatilla vulgaris	Used homeopathically for respiratory and gynaecological complaints
Conium maculatum flowering top	Contains coniine (neurotoxic alkaloid, hemlock)
Anamirta cocculus seed	Contains picrotoxin (GABA-A antagonist)
Chenopodium ambrosioides	Traditional antiparasitic herb
Oyster shell calcium carbonate, crude	Calcium source / homeopathic mineral
Phosphorus	Homeopathic mineral
Silicon dioxide	Excipient / homeopathic mineral

3. No original indication on record. Without a known starting indication, the “from → to” repurposing pathway cannot be constructed, and the model has no disease-space anchor from which to generate candidates.

Safety Considerations

No formal DDI data or package insert warnings are available for this compound. However, two ingredients warrant specific attention based on their known conventional toxicity profiles:

Strychnos nux-vomica seed contains strychnine and brucine — potent convulsants at pharmacological doses.
Conium maculatum (poison hemlock) contains coniine — a neurotoxic alkaloid associated with ascending paralysis.

In homeopathic preparations, these substances are typically diluted to sub-pharmacological concentrations (e.g., 6C, 30C). However, if this compound is to be investigated in any clinical setting, dilution level (homeopathic potency) and actual ingredient concentrations must be verified before initiating any safety or efficacy evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned no predictions because this compound cannot be mapped to the knowledge graph — it has no DrugBank ID, no US regulatory history, and no documented mechanism of action. The multi-ingredient homeopathic nature of the formulation adds further analytical complexity. None of the minimum prerequisites for a repurposing evaluation are currently met.

To proceed, the following is needed:

Assign DrugBank IDs to each active botanical ingredient (Strychnos nux-vomica, Pulsatilla vulgaris, Conium maculatum, Anamirta cocculus, Chenopodium ambrosioides)
Decide analytical strategy: evaluate as a combined formulation vs. run TxGNN separately on each ingredient and aggregate results
Locate or reconstruct a package insert to document the original indication, dosage, and safety warnings (Data Gap DG001)
Retrieve mechanism of action data from DrugBank for each constituent (Data Gap DG002)
Verify homeopathic potency and confirm whether active-ingredient concentrations are sufficient for pharmacological activity — this determines whether a conventional repurposing model like TxGNN is even the appropriate analytical framework
Re-run the full TxGNN pipeline after the above prerequisites are resolved
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.